Abstract
Neurons in the CNS establish exceedingly complex and precise networks organised via specific synaptic connections that ultimately determine the cellular basis of cognitive processes and behaviour. This fragile and intricate circuitry presents a challenging barrier for fundamental neurobiology studies or clinical gene therapy where long-term genetic modification is wanted. Small volumes, low toxicity, minimal immune reaction, slow delivery times, and preferential targeting of specific cell types in selected subregions are often sine qua non for vector-mediated gene transfer. This review addresses the state-of-the-art of gene transfer to the CNS, in particular the use of adenovirus, herpes simplex virus, adeno-associated virus, simian virus 40 (SV40), lentivirus and alphavirus vectors. The advantages and drawbacks of these molecular tools with respect to their tropism; ability to traffic via axoplasmic retrograde transport; duration of transgene expression; innate, adaptive and memory immunity; and toxicity are discussed.
Keywords: viral vectors, tropism, neurons, glia, retrograde transport, gene transfer, immune response, neurodegeneration
Current Genomics
Title: Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors
Volume: 6 Issue: 1
Author(s): E. J. Kremer
Affiliation:
Keywords: viral vectors, tropism, neurons, glia, retrograde transport, gene transfer, immune response, neurodegeneration
Abstract: Neurons in the CNS establish exceedingly complex and precise networks organised via specific synaptic connections that ultimately determine the cellular basis of cognitive processes and behaviour. This fragile and intricate circuitry presents a challenging barrier for fundamental neurobiology studies or clinical gene therapy where long-term genetic modification is wanted. Small volumes, low toxicity, minimal immune reaction, slow delivery times, and preferential targeting of specific cell types in selected subregions are often sine qua non for vector-mediated gene transfer. This review addresses the state-of-the-art of gene transfer to the CNS, in particular the use of adenovirus, herpes simplex virus, adeno-associated virus, simian virus 40 (SV40), lentivirus and alphavirus vectors. The advantages and drawbacks of these molecular tools with respect to their tropism; ability to traffic via axoplasmic retrograde transport; duration of transgene expression; innate, adaptive and memory immunity; and toxicity are discussed.
Export Options
About this article
Cite this article as:
Kremer J. E., Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors, Current Genomics 2005; 6 (1) . https://dx.doi.org/10.2174/1389202053202111
DOI https://dx.doi.org/10.2174/1389202053202111 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEXDC<sup>®</sup>) in the Palliative Treatment of Pancreatic Cancer
Current Medicinal Chemistry Role of Calcium, Vitamin D, and the Extrarenal Vitamin D Hydroxylases in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry One-Step Synthesis of 1H-1,2,3-Triazol-1-Ylmethyl-2,3-Dihydronaphtho[1,2-b]furan- 4,5-Diones
Current Organic Synthesis C-Myc Signaling Pathway in Treatment and Prevention of Brain Tumors
Current Cancer Drug Targets Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of Diseases
Current Neuropharmacology Emerging Features in the Regulation of MMP-9 Gene Expression for the Development of Novel Molecular Targets and Therapeutic Strategies
Current Drug Targets - Inflammation & Allergy Molecular Link Mechanisms between Inflammation and Cancer
Current Pharmaceutical Design EDITORIAL [Hot topic: RAS - A Central Feature in Cancer Targeted Therapy (Guest Editor: Balazs Gyorffy)
Current Cancer Drug Targets Selectively Targeted Anti-Neoplastic Cytotoxicity of Three Immunopharmaceuticals with Covalently Bound Fludarabine, Gemcitabine and Dexamethasone Moieties Synthesized Utilizing Organic Chemistry Reactions in a Multi-Stage Regimen
Current Pharmaceutical Design Editorial :
Recent Patents on CNS Drug Discovery (Discontinued) Lactate in Solid Malignant Tumors: Potential Basis of a Metabolic Classification in Clinical Oncology
Current Medicinal Chemistry Potential Advantages of Using Synchrotron X-ray Based Techniques in Pediatric Research
Current Medicinal Chemistry Alkaloid-Metal Based Anticancer Agents
Current Topics in Medicinal Chemistry Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement
Current Medicinal Chemistry Pyrimidine Nucleosides in Molecular PET Imaging of Tumor Proliferation
Current Medicinal Chemistry Drug Metabolism and Pharmacokinetics of Dammarane Triterpenoids
Current Drug Metabolism Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes
Current Drug Targets Suicide Gene Therapy Against Malignant Gliomas by the Local Delivery of Genetically Engineered Umbilical Cord Mesenchymal Stem Cells as Cellular Vehicles
Current Gene Therapy Nucleic Acid-Based Therapeutics for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Targeting of Cancers with Loss of PTEN Function
Current Drug Targets